PDCD1 and non-small cell lung carcinoma: In another study on advanced NSCLC patients treated with PD-L1/PD-1 inhibitors as the second- or third-line treatment, Dall’Olio et al. found that PD-L1+ CTCs were associated with better survival and worse survival when measured during pre-treatment and post-treatment, respectively [177].